

Refine Search

Search Results -

Term	Documents
GELATIN	171791
GELATINS	7457
ALGINATE	45213
ALGINATES	17061
(5 AND ALGINATE AND GELATIN).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	11
(L5 AND (GELATIN AND ALGINATE)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	11

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L8

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, January 18, 2005 [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND</i>			
<u>L8</u>	L5 and (gelatin and alginate)	11	<u>L8</u>
<u>L7</u>	L5 not L6	36	<u>L7</u>
<u>L6</u>	L5 and (crosslinked or crosslinking or calcium or (metal adj cation))	70	<u>L6</u>
<u>L5</u>	(coacervate or coacervation) same (virus or vector or DNA or RNA or (nucleic adj acid))	106	<u>L5</u>

L4 L3 and (virus or vector or plasmid)
L3 (coacervate adj microsphere)
L2 Garver-Robert.in.
L1 Garver-Robert-IS.in.

5 L4
6 L3
0 L2
4 L1

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 04.20.00D
Last logoff: 29dec04 17:12:48
Logon file001 18jan05 15:50:33

*** ANNOUNCEMENT ***

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED

***German Patents Fulltext (File 324)

***Beilstein Abstracts (File 393)

***Beilstein Facts (File 390)

***Beilstein Reactions (File 391)

UPDATING RESUMED

Medline (Files 154 & 155)

REMOVED

***Info Sci & Tech Abs (File 202)

***Internet & Personal Comp Abs (File 233)

***CanCorp Financials (File 491)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<

>>> of new databases, price changes, etc. <<<

KWIC is set to 50.

HIGHLIGHT set on as ' '

* * *

File 1:ERIC 1966-2004/Jul 21

(c) format only 2004 The Dialog Corporation

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 159, 5, 73

18jan05 15:50:59 User259876 Session D700.1

\$0.81 0.230 DialUnits File1

\$0.81 Estimated cost File1

\$0.11 INTERNET

\$0.92 Estimated cost this search

\$0.92 Estimated total session cost 0.230 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2005/Jan W3

(c) format only 2005 The Dialog Corp.

*File 155: Medline has resumed updating. Please see
HELP NEWS 155 for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog Corporation

*File 159: Cancerlit is no longer updating.
Please see HELP NEWS159.

File 5:Biosis Previews(R) 1969-2005/Dec W4

(c) 2005 BIOSIS

*File 5: Price change effective Jan 1, 2005. Enter HELP
RATES 5 for details.

File 73:EMBASE 1974-2005/Jan W2

(c) 2005 Elsevier Science B.V.

*File 73: Price change effective Jan 1, 2005. Enter HELP
RATES 73 for details.

Set Items Description

--- -----

?
S (COACERVATE (W) MICROSPHERE?)
502 COACERVATE
51925 MICROSPHERE?
S1 5 (COACERVATE (W) MICROSPHERE?)

?
RD
...completed examining records
S2 3 RD (unique items)

?
T S2/3,K/ALL

2/3,K/1 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

14290013 PMID: 10195878
Coacervate microspheres as carriers of recombinant adenoviruses.
Kalyanasundaram S; Feinstein S; Nicholson J P; Leong K W; Garver R I
Department of Biomedical Engineering, Johns Hopkins University,
Baltimore, Maryland 21205, USA.
Cancer gene therapy (UNITED STATES) Mar-Apr 1999, 6 (2) p107-12,
ISSN 0929-1903 Journal Code: 9432230
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Coacervate microspheres as carriers of recombinant adenoviruses.
...for bolus administration, both of which limit the efficiency of target
tissue infection. As a first step toward overcoming these limitations, rAds
were encapsulated in **coacervate microspheres** comprised of gelatin and
alginate followed by stabilization with calcium ions. Ultrastructural
evaluation showed that the microspheres formed in this manner were 0.8-10
...

... adenovirus-containing microspheres to human tumor nodules engrafted in
mice showed that the viral transgene was transferred to the tumor cells. It
is concluded that **coacervate microspheres** can be used to encapsulate
bioactive rAd and release it in a time-dependent manner.

2/3,K/2 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011313709 BIOSIS NO.: 199800107956
**Recombinant adenovirus can be encapsulated and released from coacervate
microspheres in a time-dependent fashion**
AUTHOR: Kalyanasundaram S (Reprint); Feinstein Sharon; Nicholson J P; Leong
K W (Reprint); Garver R I Jr
AUTHOR ADDRESS: Johns Hopkins Univ., Dep. Biomed. Eng., Baltimore, MD, USA
**USA
JOURNAL: Cancer Gene Therapy 4 (6 CONF. SUPPL.): pS23 Nov.-Dec., 1997 1997
MEDIUM: print
CONFERENCE/MEETING: Sixth International Conference on Gene Therapy of
Cancer San Diego, California, USA November 20-22, 1997; 19971120
ISSN: 0929-1903
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

**Recombinant adenovirus can be encapsulated and released from coacervate
microspheres in a time-dependent fashion**
DESCRIPTORS:

MISCELLANEOUS TERMS: **coacervate microspheres ;**

2/3,K/3 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

06956690 EMBASE No: 1997241258

Coacervate microspheres as vaccination vehicles

Azhari R.; Danino E.; Kasuto H.; Kushnir A.; Kothliarevski L.; Levin D.
R. Azhari, Dept. of Biotechnology, Ort Braude College, Karmiel, 20101
Israel

Proceedings of the Controlled Release Society (PROC. CONTROL. RELEASE
SOC.) (United States) 1997, -/24 (821-822)

CODEN: 58GMA ISSN: 1022-0178

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 8

Coacervate microspheres as vaccination vehicles

?

Set	Items	Description
S1	5	(COACERVATE (W) MICROSPHERE?)
S2	3	RD (unique items)

?

(COACERVATE OR COACERVATION) (S) (VIRUS OR VECTOR OR DNA OR RNA OR (NUCLEIC (W) ACID

>>>When using accession numbers with KEEP in OneSearch, you

>>>must use the FROM option to specify a file number.

?

S (COACERVATE OR COACERVATION) (S) (VIRUS OR ADENOVIRUS OR VECTOR OR RNA OR DNA)

502 COACERVATE

964 COACERVATION

1435333 VIRUS

83729 ADENOVIRUS

294296 VECTOR

1564357 RNA

2651109 DNA

S3 52 (COACERVATE OR COACERVATION) (S) (VIRUS OR ADENOVIRUS OR
VECTOR OR RNA OR DNA)

?

S S3 AND (CROSSLINKED OR CROSSLINKING)

52 S3

12185 CROSSLINKED

22625 CROSSLINKING

S4 6 S3 AND (CROSSLINKED OR CROSSLINKING)

?

RD

...completed examining records

S5 2 RD (unique items)

?

T S5/3,K/ALL

5/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

14185207 PMID: 9882427

Gene transfer by DNA-gelatin nanospheres.

Truong-Le V L; Walsh S M; Schweibert E; Mao H Q; Guggino W B; August J T;
Leong K W

Department of Pharmacology and Molecular Sciences, Johns Hopkins School
of Medicine, Baltimore, Maryland, 21205, USA.

Archives of biochemistry and biophysics (UNITED STATES) Jan 1 1999,
361 (1) p47-56, ISSN 0003-9861 Journal Code: 0372430

Contract/Grant No.: 1 RO1 A141908; PHS; CA 68011; CA; NCI
 Document type: Journal Article
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: Completed

A **DNA** and gelatin nanoparticle **coacervate** containing chloroquine and calcium, and with the cell ligand transferrin covalently bound to the gelatin, has been developed as a gene delivery vehicle. In this study, the **coacervation** conditions which resulted in the formation of distinct nanoparticles are defined. Nanospheres formed within a narrow range of **DNA** concentrations and achieved incorporation of more than 98% of the **DNA** in the reaction. **Crosslinking** of gelatin to stabilize the particles does not effect the electrophoretic mobility of the **DNA**. **DNA** in the nanosphere is partially resistant to digestion with concentrations of DNase I that result in extensive degradation of free **DNA** but is completely degraded by high concentrations of DNase. Optimum cell transfection by nanosphere **DNA** required the presence of calcium and nanospheres containing transferrin. The biological integrity of the nanosphere **DNA** was demonstrated with a model system utilizing **DNA** encoding the cystic fibrosis transport regulator (CFTR). Transfection of cultured human tracheal epithelial cells (9HTEo) with nanospheres containing this plasmid resulted in CFTR expression in...

5/3,K/2 (Item 2 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2005 The Dialog Corp. All rts. reserv.

07940010 PMID: 3189780

Use of critical point polyacrylamide sols in thermal denaturation experiments with chromatin at physiological ionic strength.

Riehm M R; Harrington R E

Department of Biochemistry, University of Nevada, Reno 89557.

Analytical biochemistry (UNITED STATES) Aug 1 1988, 172 (2) p296-303

, ISSN 0003-2697 Journal Code: 0370535

Contract/Grant No.: GM 33435; GM; NIGMS; T32 CA 09563; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Low percentage highly **crosslinked** polyacrylamide gels just above the critical point in the chemically polymerized sol to gel transition are used to generate polyacrylamide sols at critical point concentrations...

... liter-1, by mild heating. We find that chromatin samples mixed with these sols induce the sol to gel transition in a process of complex **coacervation**. In this state, salt insoluble chicken erythrocyte chromatin is stabilized against large scale aggregation and precipitation during thermal denaturation at physiological sodium ion concentrations. The hyperchromic melting behavior of **DNA** in polyacrylamide sols is reproducible and consistent throughout a wide range of sodium chloride concentrations. Empirical spectroscopic techniques are discussed which isolate temperature-dependent hyperchromic signals at 260 nm due to conformational changes of **DNA** in chromatin and local environmental changes which promote anomalous light scattering.

?

Set	Items	Description
S1	5	(COACERVATE (W) MICROSPHERE?)
S2	3	RD (unique items)
S3	52	(COACERVATE OR COACERVATION) (S) (VIRUS OR ADENOVIRUS OR V- ECTOR OR RNA OR DNA)
S4	6	S3 AND (CROSSLINKED OR CROSSLINKING)

```

S5          2    RD (unique items)
?
RD S3
...examined 50 records (50)
...completed examining records
      S6        27    RD S3 (unique items)
?
S S6 NOT S5
                27    S6
                2     S5
      S7        25    S6 NOT S5
?
S S7 NOT PY>1998
                25    S7
      9441772    PY>1998
      S8        10    S7 NOT PY>1998
?
T S8/3,K/ALL

```

8/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2005 The Dialog Corp. All rts. reserv.

14041285 PMID: 9741926

DNA-polycation nanospheres as non-viral gene delivery vehicles.

Leong K W; Mao H Q; Truong-Le V L; Roy K; Walsh S M; August J T
 Department of Biomedical Engineering, Johns Hopkins University,
 Baltimore, MD 21205, USA. kleong@bme.jhu.edu

Journal of controlled release - official journal of the Controlled
 Release Society (NETHERLANDS) Apr 30 1998, 53 (1-3) p183-93, ISSN
 0168-3659 Journal Code: 8607908

Contract/Grant No.: CA68011; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Nanospheres synthesized by salt-induced complex **coacervation** of cDNA and polycations such as gelatin and chitosan were evaluated as gene delivery vehicles. **DNA** -nanospheres in the size range of 200-750 nm could transfect a variety of cell lines. Although the transfection efficiency of the nanospheres was typically...

...phosphate controls in cell culture, the beta-gal expression in muscle of BALB/c mice was higher and more sustained than that achieved by naked **DNA** and lipofectamine complexes. This gene delivery system has several attractive features: (1) ligands can be conjugated to the nanosphere for targeting or stimulating receptor-mediated endocytosis; (2) lysosomolytic agents can be incorporated to reduce degradation of the **DNA** in the endosomal and lysosomal compartments; (3) other bioactive agents or multiple plasmids can be co-encapsulated; (4) bioavailability of the **DNA** can be improved because of protection from serum nuclease degradation by the polymeric matrix; (5) the nanosphere can be lyophilized for storage without loss of...

8/3,K/2 (Item 2 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2005 The Dialog Corp. All rts. reserv.

14020755 PMID: 9721081

Controlled gene delivery by DNA-gelatin nanospheres.

Truong-Le V L; August J T; Leong K W
 Department of Pharmacology and Molecular Sciences, The Johns Hopkins
 University School of Medicine, Baltimore, MD 21205, USA.

Human gene therapy (UNITED STATES) Aug 10 1998, 9 (12) p1709-17,
ISSN 1043-0342 Journal Code: 9008950
Contract/Grant No.: 1-ROI-AI41908; AI; NIAID; AI42718; AI; NIAID; P50
CA62924; CA; NCI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

A novel system for gene delivery, based on the use of **DNA** -gelatin nanoparticles (nanospheres) formed by salt-induced complex **coacervation** of gelatin and plasmid **DNA** , has been developed. These particles were spherical, with a size range of 200-700 nm, contained 25-30% (w/w) **DNA** , and were stabilized by cross-linking of gelatin. As a consequence of being controlled by the cross-linking density of the gelatin matrix, the average release rate of **DNA** from nanospheres synthesized under standard conditions was 2.2%/day in serum. Nanosphere **DNA** incubated in bovine serum was more resistant to nuclease digestion than was naked **DNA** . Various bioactive agents could be encapsulated in the nanospheres by ionic interaction with the matrix components, physical entrapment, or covalent conjugation. Transfection of cultured cells...

... nanospheres containing 1 microg of a beta-galactosidase plasmid was greater and more prolonged than was observed after injection of an equal amount of naked **DNA** or **DNA** complexed with Lipofectamine.

8/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2005 The Dialog Corp. All rts. reserv.

06578676 PMID: 6462688
Present state of the coacervate-in-coacervate theory; origin and evolution of cell structure.
Novak V J
Origins of life (NETHERLANDS) 1984, 14 (1-4) p513-22, ISSN
0302-1688 Journal Code: 0420542
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

In agreement with the views of Oparin, Fox, Dose etc., the theory assumes that **coacervation** of protein-like polyaminoacids began with their accumulation along the coasts of the Archaic water basins. Unlike the above authors, however, the present author views...

... on the basis of their mutual affinity. The polyfunctional enzymic activity of the proteinoids catalyzed their replication as well as other activities. Around the replicating **DNA** molecules secondary coacervates (coacervates in coacervates) accumulated which developed gradually to the first prokaryotic cells. Their most probable evolution to the first eukaryotic organisms is...

8/3,K/4 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011313709 BIOSIS NO.: 199800107956
Recombinant adenovirus can be encapsulated and released from coacervate microspheres in a time-dependent fashion
AUTHOR: Kalyanasundaram S (Reprint); Feinstein Sharon; Nicholson J P; Leong K W (Reprint); Garver R I Jr
AUTHOR ADDRESS: Johns Hopkins Univ., Dep. Biomed. Eng., Baltimore, MD, USA

**USA

JOURNAL: Cancer Gene Therapy 4 (6 CONF. SUPPL.): pS23 Nov.-Dec., 1997 1997
MEDIUM: print
CONFERENCE/MEETING: Sixth International Conference on Gene Therapy of
Cancer San Diego, California, USA November 20-22, 1997; 19971120
ISSN: 0929-1903
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

Recombinant adenovirus can be encapsulated and released from coacervate microspheres in a time-dependent fashion

8/3,K/5 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0009982668 BIOSIS NO.: 199598450501

Experimental retracement of the origins of a protocell: It was also a protoneuron

AUTHOR: Fox Sidney W (Reprint); Bahn Peter R; Dose Klaus; Harada Kaoru; Hsu Laura; Ishima Yoshio; Jungck John; Kendrick Jean; Krampitz Gottfried; Lacey James C Jr; Matsuno Koichiro; Melius Paul; Middlebrook Mavis; Nakashima Tadayoshi; Pappelis Aristotel; Pol Alexander; Rohlfing Duane L; Vegotsky Allen; Waehneltd Thomas V; Wax H; Yu Bi
AUTHOR ADDRESS: Coastal Res. Dev. Inst., LSB 124, Univ. South Alabama, Mobile, AL 36688, USA**USA
JOURNAL: Journal of Biological Physics 20 (1-4): p17-36 1994 (1995) 1994
ISSN: 0092-0606
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Although Oparin used **coacervate** droplets from two or more types of polymer to model the first cell, he hypothesized homacervation from protein, consistent with Pasteur and Darwin. Herrera made...

...protoneurons and networks thereof, and numerous industrial applications of thermal polyamino acids. Life itself has thus been reaffirmed to be rooted in protein, not in **DNA** nor **RNA**, which are however crucial to inheritance in modern life as 'instruction manuals' (Komberg). Recognition of the advances have been considerably delayed by the deeply held assumption that life began by chance from random polymerization of amino acids, in contrast to the experimental findings. The concepts of **DNA / RNA** -first and protein-first are reconciled by a rise-and-fall progression as often seen in biochemical and biological evolution. The fact that amino acids...

8/3,K/6 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0009214073 BIOSIS NO.: 199497235358

Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments

AUTHOR: Cortesi Rita; Esposito Elisabetta; Menegatti Enea; Gambari Roberto; Nastruzzi Claudio (Reprint)
AUTHOR ADDRESS: Dep. Pharmaceutical Sci., Ferrara Univ., Via Fossato di Mortara 19, I-44100 Ferrara, Italy**Italy
JOURNAL: International Journal of Pharmaceutics (Amsterdam) 105 (2): p 181-186 1994 1994
ISSN: 0378-5173
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: length, prepared by the polymerase chain reaction (PCR) mimicking a region of the HIV-1 LTR (dsDNA-144). Spherical gelatin microspheres were obtained by a **coacervation** method, showing a high percentage of encapsulation yields (over 85%). Size distribution analysis of the microspheres produced resulted in an average diameter of 22 μ ...

...a flow-through cell method. The chemical stability of dsDNA-144 to the encapsulation procedure steps was in addition demonstrated by PCR amplification of the **DNA** eluted from the gelatin microspheres. The reported results indicate that gelatin-based microspheres offer excellent potential as carrier systems of the in vivo administration of both single- and double-stranded **DNA** molecules.

8/3,K/7 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0002929802 BIOSIS NO.: 198069043789

THE EVOLUTION OF BIOLOGICAL MACRO MOLECULES 1. PHYSICOCHEMICAL SELF ORGANIZATION

AUTHOR: EBELING W (Reprint); FEISTEL R
AUTHOR ADDRESS: SEKT PHYS, WILHELM-PIECK-UNIV, UNIVERSITAETSPLATZ 3, DDR-25 ROSTOCK, E GER**EAST GERMANY
JOURNAL: Studia Biophysica 75 (2): p131-146 1979
ISSN: 0081-6337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: of biogenesis is presented which combines the basic ideas of Oparin and Eigen. Based on this model the hypothesis is developed that the competition of **coacervate** -microreactors played an important role in the primordial selection processes. Further binary catalytic cycles, catalytic cascades and **RNA** -replicase cycles are the most probable precursors for the evolution of more complex structures.

DESCRIPTORS: MATHEMATICAL MODEL **COACERVATE** MICRO REACTOR COMPETITION PRIMORDIAL SELECTION BINARY CATALYTIC CYCLE CATALYTIC CASCADE **RNA** REPLICASE CYCLE

8/3,K/8 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0002582406 BIOSIS NO.: 197917031401

A MICRO ENCAPSULATION SYSTEM FOR THE PROTECTION OF MICROBIAL INSECTICIDES FROM SUN LIGHT INACTIVATION

AUTHOR: ANDREWS R E; SPENCE K D
JOURNAL: Abstracts of the Annual Meeting of the American Society for Microbiology (79): p236 1979
ISSN: 0094-8519
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: Unspecified

DESCRIPTORS: ABSTRACT **RNA** PROTEIN **COACERVATE** MICRO BEADS SPORES

8/3,K/9 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0001905629 BIOSIS NO.: 197662001768

**DEPENDENCE OF THE CONTENT AND CONCENTRATION OF ENZYMATIC OXIDATION PRODUCTS
ON SIZE OF COACERVATE DROPLETS**

AUTHOR: MAMONTOVA T V; EVREINOVA T N; KHRUST YU R

JOURNAL: Doklady Akademii Nauk SSSR Seriya Biologiya 223 (4): p1020-1022
1975

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: Unspecified

ABSTRACT: Quantitative measurements were made of stabilizing oxidation products in individual **coacervate** droplets and the relation between the size of the droplets and their content of oxidized compounds was established. Protein-carbohydrate **coacervate** systems consisting of histone and gum arabic and protein-nucleic acid **coacervate** systems consisting of histone and **DNA** were investigated. The content and concentration of oxidized compounds was higher in the **coacervate** droplets consisting of **DNA** and histone than in droplets of gum arabic and histone of the same size. Protein-nucleic acid **coacervate** droplets have a slightly greater ability to concentrate products of enzymatic oxidation. The stable **coacervate** systems obtained broaden their use as precellular models.

8/3,K/10 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

06237497 EMBASE No: 1995274686

Gene transfer by gelatin- DNA coacervate

Truong-Le V.L.; Walsh S.M.; August J.T.; Leong K.W.

Dept. Pharmacol. Molecular Sciences, The Johns Hopkins

University, Baltimore, MD 21205 United States

Proceedings of the Controlled Release Society (PROC. CONTROL. RELEASE

SOC.) (United States) 1995, -/22 (466-467)

CODEN: 58GMA ISSN: 1022-0178

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH

Gene transfer by gelatin- DNA coacervate

?

Set	Items	Description
S1	5	(COACERVATE (W) MICROSPHERE?)
S2	3	RD (unique items)
S3	52	(COACERVATE OR COACERVATION) (S) (VIRUS OR ADENOVIRUS OR V- ECTOR OR RNA OR DNA)
S4	6	S3 AND (CROSSLINKED OR CROSSLINKING)
S5	2	RD (unique items)
S6	27	RD S3 (unique items)
S7	25	S6 NOT S5
S8	10	S7 NOT PY>1998
?		
S		(COACERVATE) (S) (GELATIN AND ALGINATE)
	502	COACERVATE
	37362	GELATIN
	14490	ALGINATE
S9	8	(COACERVATE) (S) (GELATIN AND ALGINATE)
?		
S		S9 AND (VIRAL OR VIRUS OR ADENOVIRUS)
	8	S9
	785919	VIRAL
	1435333	VIRUS

83729 ADENOVIRUS

S10 3 S9 AND (VIRAL OR VIRUS OR ADENOVIRUS)

?

RD

...completed examining records

S11 1 RD (unique items)

?

T S11

11/2/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

14290013 PMID: 10195878

Coacervate microspheres as carriers of recombinant adenoviruses.

Kalyanasundaram S; Feinstein S; Nicholson J P; Leong K W; Garver R I
Department of Biomedical Engineering, Johns Hopkins University,
Baltimore, Maryland 21205, USA.

Cancer gene therapy (UNITED STATES) Mar-Apr 1999, 6 (2) p107-12,

ISSN 0929-1903 Journal Code: 9432230

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Tags: Human; Support, Non-U.S. Gov't

Descriptors: *Adenoviridae--genetics--GE; *Gene Therapy--methods--MT;
*Microspheres; Animals; Calcium--pharmacology--PD; Cytomegalovirus
--metabolism--ME; Dose-Response Relationship, Drug; Genetic Vectors;
Luciferase--metabolism--ME; Lung Neoplasms--therapy--TH; Mice; Mice, Nude;
Microscopy, Confocal; Microscopy, Electron, Scanning; Neoplasms,
Experimental--therapy--TH; Time Factors

CAS Registry No.: 0 (Genetic Vectors); 7440-70-2 (Calcium)

Enzyme No.: EC 1.13.12.- (Luciferase)

Record Date Created: 19990607

Record Date Completed: 19990607

?

RD S9

...completed examining records

S12 3 RD S9 (unique items)

?

S S12 NOT S11

3 S12

1 S11

S13 2 S12 NOT S11

?

T S13/3,K/ALL

13/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

14044778 PMID: 9743913

beta-Glucuronidase activity following complex coacervation and spray drying microencapsulation.

Burgess D J; Ponsart S

Department of Pharmaceutical Sciences, School of Pharmacy, University of
Connecticut, Storrs 06269, USA.

Journal of microencapsulation (ENGLAND) Sep-Oct 1998, 15 (5) p569-79

, ISSN 0265-2048 Journal Code: 8500513

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...process suitable for the controlled release of an active protein drug. beta-glucuronidase was selected as a model protein and a combination of complex coacervation (**gelatin** /sodium **alginate** , ☐gelatin☐ /acacia and albumin/acacia) and spray drying was investigated. Coacervates were either spray dried or glutaraldehyde crosslinked to form microcapsules. Polyvinylpyrrolidone (PVP) and polyethylene glycol were investigated as potential **coacervate** enhancers and stabilizers. beta-glucuronidase/polymer mixtures were spray dried to determine any polymer protective effects on protein activity. A BUCHI 190 Spray Drier was...

13/3,K/2 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0010217379 BIOSIS NO.: 199698685212

Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates

AUTHOR: Joseph Ishmael; Venkataram Suresh (Reprint)
AUTHOR ADDRESS: Fac. Pharmacy, Univ. Manitoba, Winnipeg, MB R3T 2N2, Canada
**Canada
JOURNAL: International Journal of Pharmaceutics (Amsterdam) 126 (1-2): p 161-168 1995 1995
ISSN: 0378-5173
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: crystals with gastrointestinal mucosa at high concentrations, as may happen with immediate release dosage forms. Indomethacin (IMC) sustained release microparticles (pellets) were prepared from pectin-**gelatin** or **alginate** - ☐gelatin☐hydrocolloid☐coacervate☐systems under controlled pH and temperature conditions. Delayed release up to 14 h was obtained with pectin- **gelatin** or **alginate** - ☐gelatin☐systems of varying composition. With the pectin- **gelatin** systems a low drug to hydrocolloid ratio and low pectin to **gelatin** ratio was the most optimal composition for sustained release. Incorporation of additives such as carnauba wax was essential for diffusion controlled mechanisms to operate in the **alginate** - **gelatin** systems. Additives also showed improvements in particle shape, size distribution and flow properties. The results of this study offer an inexpensive alternative form of sustained...

?

Set	Items	Description
S1	5	(COACERVATE (W) MICROSPHERE?)
S2	3	RD (unique items)
S3	52	(COACERVATE OR COACERVATION) (S) (VIRUS OR ADENOVIRUS OR VECTOR OR RNA OR DNA)
S4	6	S3 AND (CROSSLINKED OR CROSSLINKING)
S5	2	RD (unique items)
S6	27	RD S3 (unique items)
S7	25	S6 NOT S5
S8	10	S7 NOT PY>1998
S9	8	(COACERVATE) (S) (GELATIN AND ALGINATE)
S10	3	S9 AND (VIRAL OR VIRUS OR ADENOVIRUS)
S11	1	RD (unique items)
S12	3	RD S9 (unique items)
S13	2	S12 NOT S11

?

COST

18jan05 16:05:24 User259876 Session D700.2
\$3.19 0.996 DialUnits File155
\$0.21 1 Type(s) in Format 2
\$1.47 7 Type(s) in Format 3
\$1.68 8 Types

\$4.87 Estimated cost File155
\$0.81 0.274 DialUnits File159
\$0.81 Estimated cost File159
\$5.55 0.965 DialUnits File5
\$16.00 8 Type(s) in Format 3
\$16.00 8 Types
\$21.55 Estimated cost File5
\$7.77 0.730 DialUnits File73
\$5.88 2 Type(s) in Format 3
\$5.88 2 Types
\$13.65 Estimated cost File73
OneSearch, 4 files, 2.966 DialUnits FileOS
\$3.75 INTERNET
\$44.63 Estimated cost this search
\$45.55 Estimated total session cost 3.196 DialUnits
?

Return to logon page!



Day : Tuesday
Date: 1/18/2005
Time: 13:47:14

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**PALM INTRANET**

Day : Tuesday
Date: 1/18/2005
Time: 13:47:14

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)